Abstract:Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2-3 years from human and preclinical animal studies, together with the structural-functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Pro-resolving lipid mediators are leads for resolution physiology

Specialized pro-resolving mediator network: an update on production and actions

Resolvins and protectins in the termination program of acute inflammation

The Research Progress of Resolvin Reducing Pulmonary Inflammation

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

[Mechanism of Resolvins in Reducing the Inflammation Reaction in Inflammatory Diseases].

Endogenous Pro-Resolving and Anti-Inflammatory Lipid Mediators: the New Hope of Atherosclerotic Diseases.

Resolvin E1 and protectin D1 activate inflammation-resolution programmes

Specialized pro-resolving mediators - Key players in resolution

Old and new generation lipid mediators in acute inflammation and resolution

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Roles of Resolvins in Chronic Inflammatory Response

Design of nanoformulation of specialized pro-resolving mediators to facilitate inflammation resolution and disease treatment

Role of Specialized Pro-Resolving Lipid Mediators in Pulmonary Inflammation Diseases: Mechanisms and Development

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases